Current Studies:
Oncology - Clinical Studies
NEW!! Enrolling April 2012
The Impact of Multi-kinase Inhibitor Palladia™ on Angiogenesis and Survival following Amputation and Carboplatin Chemotherapy in Canine Osteosarcoma
* This study supported by a grant from Bone Cancer Dogs
Description: Osteosarcoma is the most common bone cancer in dogs. Tumors are locally invasive and have a high rate of metastasis (spread to other places in the body). We are evaluating the use of a novel approach to the treatment of osteosarcoma involving the use of an oral medication (Palladia™) following standard of care treatment (amputation and four cycles of carboplatin chemotherapy). Palladia™ has the ability to disrupt the blood supply to tumor cells and may therefore help delay or prevent the onset of metastasis.
Eligibility: Dogs with appendicular osteosarcoma with no radiographic evidence of pulmonary metastasis following amputation and four cycles of carboplatin chemotherapy.
Study outline:
Initial Evaluation and Treatment Physical Exam, complete blood count, chemistry panel, urinalysis, 3-view thoracic radiographs; amputation; four cycles of carboplatin chemotherapy
Study Two weeks following completion of carboplatin chemotherapy dogs will begin receiving oral Palladia™ and treatment will be continued until disease progression
Clients will need to bring their pet in for evaluation according to the following schedule:
Initial Consultation
Amputation (may be performed with either the primary veterinarian or NCSU)
Chemotherapy 10-14 days after amputation, begin 4 cycles of carboplatin chemotherapy given at 3-week intervals
Palladia 2 weeks after final carboplatin treatment, complete blood count, serum chemistry, serum for assay collection, urinalysis, 3-view thoracic radiographs and begin Palladia™ treatment
Week 1,2 and 3 of Palladia™ Bloodwork
Monthly therafter Bloodwork (every visit) and thoracic radiographs (every other visit)
Financial Incentive: The study will cover the costs of Palladia™ and blood work associated with drug monitoring. Clients will be responsible for costs associated with initial evaluation, amputation, and every other month thoracic radiographs.
Who to contact: If you have any questions about this study or have a patient (or pet) that may be eligible, please contact study coordinator, Ms. Julie Nettifee Osborne, RVT, at (919) 513-6812 or via email at julie_osborne@ncsu.edu.
Pulse Palladia plus CCNU for the Treatment of Measurable Canine Mast Cell Tumors
Description: Mast cell tumors are one of the most common skin tumors in dogs. Conventional treatment consists of surgery +/-radiation therapy. In some situations, however, tumors are highly malignant, inoperable and/or have spread to other places in the body, making systemic chemotherapy a worthwhile part of treatment. To date, studies have focused on the use of single or combined chemotherapy protocols consisting of prednisone, vinblastine, and CCNU, with response rates of approximately 20-45% lasting for a few to several months. More recently, a new drug called Palladia has been developed specifically for the treatment of canine mast cell tumors. This drug works in a unique way, targeting a specific mutation present in mast cell tumors. Response rates to Palladia are approximately 40-45%. The goal of the current study is to evaluate the combination of conventional CCNU chemotherapy with Palladia in hopes of improving outcome for dogs with mast cell tumors. This study will also determine the optimal dosage of combined CCNU and Palladia in dogs.
Eligibility: Dogs with measurable mast cell tumors.
Financial incentive: The study will provide the chemotherapy drugs CCNU and Palladia and will cover the majority of costs of blood work performed as part of treatment monitoring. Clients will be responsible for costs associated with initial evaluation, recheck visit evaluations, and any concurrent medications.
Who to contact: Study coordinator, Ms. Julie Nettifee Osborne, RVT, at (919) 513-6812 or via email at julie_osborne@ncsu.edu.
Impact of Palladia™ on Canine Osteosarcoma
Description: Osteosarcoma is the most common bone cancer in dogs. Tumors are locally invasive and have a high rate of metastasis (spread to other places in the body). We are evaluating the use of a novel approach to the treatment of ostesarcoma involving the use of an oral medication (Palladia™) following amputation. Palladia™ has the ability to disrupt the blood supply to tumor cells and may therefore help delay or prevent the onset of metastasis.
Eligibility: Dogs with appendicular osteosarcoma with no radiographic evidence of pulmonary metastasis undergoing amputation
Study outline:
Initial Evaluation Physical Exam, complete blood count, chemistry panel, urinalysis, 3-view thoracic radiographs
Treatment Five days following amputation, dogs will begin receiving oral Palladia™ and treatment will be continued until disease progression
Clients will need to bring their pet in for evaluation according to the following schedule:
Initial Consultation
Amputation (may be performed with either the primary veterinarian or NCSU)
Within 5 days after amputation Bloodwork and begin Palladia™ treatment
Week 1,2 and 3 of Palladia® Bloodwork
Monthly therafter Bloodwork (every visit) and thoracic radiographs (every other visit)
Financial Incentive: The study will cover the costs of Palladia™ and blood work associated with drug monitoring. Clients will be responsible for costs associated with initial evaluation, amputation, and every other month thoracic radiographs.
Who to contact: If you have any questions about this study or have a patient (or pet) that may be eligible, please contact study coordinator, Ms. Julie Nettifee Osborne, RVT, at (919) 513-6812 or via email at julie_osborne@ncsu.edu.